

Telefax: +91 1127679700-05 (6 Lines) e mail: info@insecticidesindia.com www.insecticidesindia.com CIN: L65991DL1996PLC083909 (INDIA) LIMITED

Regd. & Corporate Office: 401-402, Lusa Tower Azadpur Commercial Complex, Delhi - 110 033

Ref: IIL/SE/2024/0908/01 Date: August 09, 2024

The Manager

| Listing Compliance Department | Listing Compliance Department |
|--------------------------------------|--|
| BSE Limited | National Stock Exchange of India Limited |
| (Through BSE Listing Centre) | (Through NEAPS) |
| | , |
| Scrip Code: 532851 | Symbol: INSECTICID |

Dear Sir/Madam,

Re: Outcome of the Board Meeting

This has reference to our letter no. IIL/SE/2024/2207/1 dated July 22, 2024 and IIL/SE/2024/2307/1 dated July 23, 2024.

The Board of Directors of the Insecticides (India) Limited/the Company ("Board") at their meeting held today i.e August 09, 2024, *inter alia* transacted the following business:

- 1. Considered and approved the Un-audited Standalone and Consolidated Financial Results of the Company, for the Quarter ended June 30, 2024 along with Limited Review Report of M/s S S Kothari Mehta & Co., LLP and M/s Devesh Parekh & Co., Joint Statutory Auditors of the Company on the Financial Statements. The Financial Results were reviewed and recommended by the Audit Committee. Accordingly, we enclosed the following as Annexure I:
 - Un-audited Standalone and Consolidated Financial Results for the first Quarter ended on June 30, 2024.
 - Limited Review Report of the Statutory Auditor(s) on the Un-audited Standalone and Consolidated Financial Results for the first Quarter ended on June 30, 2024.

A copy of the said results together with the Auditor's report are also being made available on the website of the Company at www.insecticidesindia.com.

Declared an Interim Dividend of Rs. 2.00/- per equity shares [20%] of face value of Rs. 10/-2. each for financial year 2024-2025. The record date as informed for the purpose of determining for entitlement of the shareholders for the payment of Interim Dividend is Friday, 23rd day of August, 2024 and the Interim Dividend will be paid to the shareholders, subject to deduction/withholding of applicable taxes, within the time prescribed under law. The Interim Dividend will be paid on or from August 28, 2024.





Regd. & Corporate Office: 401-402, Lusa Tower

3. On the recommendation of Nomination Remuneration and Ethics Committee, the Board of Directors approved the appointment of Mr. Dushyant Sood as a Chief Marketing Officer (CMO) of the Company w.e.f August 09, 2024.

Brief profile and other details required under regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 and read with SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure II.

4. To windup or dissolve the "IIL Overseas DMCC", Dubai, a wholly owned subsidiary of the Company at Dubai, United Arab Emirates (UAE) according to the Registrar of Companies of the Dubai Multi Commodities Centre Authority (DMCCA).

It may be noted that the IIL Overseas DMCC is not a material subsidiary of the Company and has not commenced its business activities.

It may also be noted that the dissolution of the above subsidiary will not affect any business or revenue and will not have any significant impact on the accounts.

The details required under regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 and read with SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure III.

The Board meeting commenced at 01:30 PM (IST) and concluded at 03:00 PM (IST)

You are requested to kindly take on records.

Thanking You, For Insecticides India Limited

(Sandeep Kumar)

Company Secretary & CCO

Encl: As above

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033; Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

| | | ("₹" In Lacs, except EPS) | | | |
|--------|---|---------------------------|---|--|--|
| | | Quarter Ended | | | Year Ended |
| SI No. | Particulars | 30-06-2024 (Unaudited) | 31-03-2024 (Audited) (Refer note 6) | 30-06-2023 (Unaudited) | 31-03-2024 (Audited) |
| 1 | Revenue from operations | 65,668.53 | 27,250.21 | 63,995.34 | 1,96,638.55 |
| П | Other Income | 253.88 | 455.82 | 388.73 | 950.67 |
| Ш | Total Income (I+II) | 65,922.41 | 27,706.03 | 64,384.07 | 1,97,589.22 |
| IV | Expenses | | | | -,-,,, |
| | (a) Cost of materials consumed | 33,912.44 | 27,010.22 | 41,001.01 | 1,33,219.31 |
| | (b) Purchase of Stock-in-Trade | 2,098.13 | 766.06 | 4,427.49 | 15,885.66 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 11,591.26 | (9,210.44) | 5,264.58 | (2,602.36) |
| | (d) Employee benefits expense | 3,863.18 | 2,569.14 | 2,964.45 | 11,722.13 |
| | (e) Finance costs | 162.47 | 206.95 | 316.64 | 1,088.35 |
| | (f) Depreciation and amortization expense | 713.01 | 759.85 | 688.07 | 2,924.85 |
| | (g) Other expenses | 7,020.58 | 5,189.21 | 5,772.91 | 22,093.29 |
| | Total expenses | 59,361.07 | 27,290.99 | 60,435.15 | 1,84,331.23 |
| v | Profit before tax (III-IV) | 6,561.34 | 415.04 | 3,948.92 | 12.255.00 |
| VI | Tax Expense | 0,501.54 | 415.04 | 3,948.92 | 13,257.99 |
| | (1) Current Tax | 1,721.39 | (150.27) | 1,072.01 | 2 206 17 |
| | (2) Deferred Tax | (73.64) | (242.61) | The second secon | 3,295.17 |
| | Total Tax Expense | 1,647.75 | (392.88) | (26.20) 1,045.81 | (299.73) 2,995.44 |
| VII | Profit for the period (V-VI) | 4,913.59 | 807.92 | 2,903.11 | 10,262.55 |
| | | | | | FIGURE AND |
| VIII | Other comprehensive income | | | | |
| A | Items that will not be reclassified to profit or loss | | | | |
| | (i) Changes in fair value of FVTOCI equity instruments | (218.37) | 111.36 | 215.83 | 221.09 |
| | (ii) Remeasurement of net defined benefit plans | (1.25) | 56.46 | (20.00) | (3.54) |
| | (iii) Income tax relating to these items | 51.19 | (40.15) | (45.24) | (50.61) |
| | Other comprehensive income for the period (net of tax) | (168.43) | 127.67 | 150.59 | 166.94 |
| IX | Total comprehensive income for the period (VII+VIII) | 4,745.16 | 935.59 | 3,053.70 | 10,429.49 |
| | Paid up equity share capital (Face value of ₹10/- each) | 2,959.78 | 2,959.78 | 2,959.78 | 2,959.78 |
| | Other Equity | | | - | 98,150.64 |
| | Earnings per share (of ₹10 each) | | | | |
| | (a) Basic | 16.60 | 2.73 | 9.81 | 34.67 |
| | (b) Diluted (Note: EPS for respective quarters are not annualized) | 16.60 | 2.73 | 9.81 | 34.67 |



CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033; Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

Notes:

- The above Unaudited Standalone Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on August 09, 2024. The Statutory Auditors have carried out a limited review of financial results. The Limited Review Report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com.
- The Board of Directors have declared an interim dividend of ₹ 2/- per equity share at its meeting held on August 09, 2024.
- The above Standalone financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
- The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical & Formulation.
- The Company's wholly owned subsidiary IIL Biologicals Limited has successfully completed the rights issue of Equity Shares of INR 200.00 Lakhs on June 28, 2024.
- The figures of the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year-to-date figures for nine months ended December 31, 2023, respectively.

For and on behalf of the Board

Rajesh Kumar Aggarwal lanaging Director

DIN: 00576872

Place: Delhi Date: 09/08/2024

S S KOTHARI MEHTA & CO. LLP

DEVESH PAREKH & CO.

Chartered Accountants Plot No. 68, Okhla Industrial Area, Phase-III New Delhi -110020

Chartered Accountants 675, Aggarwal Cyber Plaza-2, Netaji Subhash Place, Pitampura, Delhi-110034

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Insecticides (India) Limited Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors Insecticides (India) Limited Delhi

Review Report on the Unaudited Standalone Financial Results

- We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Insecticides (India) Limited (the "Company") for the quarter ended June 30, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





S S KOTHARI MEHTA & CO. LLP

DEVESH PAREKH & CO.

Chartered Accountants Plot No. 68, Okhla Industrial Area, Phase-III New Delhi -110020

Chartered Accountants 675, Aggarwal Cyber Plaza-2, Netaji Subhash Place, Pitampura, Delhi-110034

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S S Kothari Mehta & Co. LLP

Chartered Accountants

Firm's registration number: 000756N/ N500441

Vijay Kumar

Partner

Membership number: 092671

UDIN: 24092671BKFBQP9411

Place: Delhi

Date: 9th August, 2024

For Devesh Parekh & Co.

Chartered Accountants

Firm's registration number: 013338N

Devesh Parekh

Partner

Membership number: 092160

UDIN: 24092160

Place: Delhi


Date: 9th August, 2024

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033; Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

("₹" In Lacs, except EPS)

| | | | Quarter Ended | | Year Ended |
|-----------|--|---------------|----------------|-------------|-------------|
| SI No. | Particulars | 30-06-2024 | 31-03-2024 | 30-06-2023 | 31-03-2024 |
| OI 110. | Talterials | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| | | (Giladdied) | (Refer note 6) | (Chaudhed) | (Addited) |
| 1 | Revenue from operations | 65,668.53 | 27,250.21 | 63,995.34 | 1,96,638.55 |
| II | Other Income | 251.53 | 453.48 | 388.73 | 946.77 |
| m | Total Income (I+II) | 65,920.06 | 27,703.69 | 64,384.07 | 1,97,585.32 |
| IV | Expenses | 05,720.00 | 21,103.09 | 04,304.07 | 1,77,303.32 |
| | (a) Cost of materials consumed | 33,911.56 | 27,011.08 | 41,001.01 | 1,33,220.17 |
| | (b) Purchase of Stock-in-Trade | 2,098.13 | 766.06 | 4,427.49 | 15,885.66 |
| | | 2,078.13 | 700.00 | 4,427.45 | 13,883.00 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in- trade | 11,599.70 | (9,215.04) | 5,264.58 | (2,606.96) |
| - 10 | (d) Employee benefits expense | 3,884.57 | 2,580.22 | 2,964.45 | 11,733.21 |
| | (e) Finance costs | 163.19 | 207.42 | 316.64 | 1,088.82 |
| - 49 | (f) Depreciation and amortization expense | 713.34 | 760.02 | 688.07 | 2,925.02 |
| - 13 | (g) Other expenses | 7,024.24 | 5,211.89 | 5,772.97 | 22,151.25 |
| | Total expenses | 59,394.73 | 27,321.65 | 60,435.21 | 1,84,397.17 |
| v | Profit before tax and share of net profit of investment accounted for using equity method (III-IV) | 6,525.33 | 382.04 | 3,948.86 | 13,188.15 |
| VI | Share of net profit of joint venture accounted for using the equity method | 17.83 | (5.33) | 11.10 | 31.01 |
| VII | Profit Before Tax (V+VI) | 6,543.16 | 376.71 | 3,959.96 | 13,219.16 |
| VIII | Tax Expense | 0,040,110 | 570.71 | 5,7,7,70 | 10,217.10 |
| VIII | (1) Current Tax | 1,721.39 | (150.27) | 1,072.01 | 3,295.17 |
| | (2) Deferred Tax | (79.71) | (249.38) | (26.20) | (312.53) |
| - 1 | Total Tax Expense | 1,641.68 | (399.65) | 1,045.81 | 2,982.64 |
| | Total Tax Expense | 1,041.00 | (377.03) | 1,043.01 | 2,702,04 |
| IX | Profit for the period (VII - VIII) | 4,901.48 | 776.36 | 2,914.15 | 10,236.52 |
| 1440000 | Profit attributable to Owners' | 4,901.48 | 776.36 | 2,914.15 | 10,236.52 |
| | Profit attributable to Non Controlling Interest | • | - | | |
| x | Other comprehensive income | | | | |
| A | Items that will not be reclassified to profit or loss | | | | |
| 201 | (i) Changes in fair value of FVTOCI equity instruments | (218.37) | 111.36 | 215.83 | 221.09 |
| | (ii) Remeasurement of net defined benefit plans | (1.25) | 56.46 | (20.00) | (3.54) |
| | (iii) Share of Other comprehensive income of joint venture accounted for | | | | |
| | using equity method | (4,31) | 12.54 | (0.92) | 11.85 |
| | (iv) Income tax relating to these items | 52.27 | (43.31) | (45.01) | (53.60) |
| ** | | | | | |
| В | Items that will be reclassified to profit or loss | | | | |
| | (i) Exchange differences in translating the financial statements of | (0.01) | | | |
| | foreign operations | (171 (7) | 127.05 | 140.00 | 185.00 |
| | Other comprehensive income for the period (net of tax) | (171.67) | 137.05 | 149.90 | 175.80 |
| XI | Total comprehensive income for the period (IX+X) | 4,729.81 | 913.41 | 3,064,05 | 10,412.32 |
| 1 1021110 | Other comprehensive income attributable to Owners' | (171.67) | 137.05 | 149.90 | 175.80 |
| 300 | Other comprehensive income attributable to Non Controlling Interest | (1/1.0/) | 137.00 | 145.50 | 175.00 |
| | Total comprehensive income attributable to Owners' | 4,729.81 | 913.41 | 3,064.05 | 10,412.32 |
| | Total comprehensive income attributable to Non Controlling Interest | A HISTORY SEE | | - | - |
| | D-12 14 d 14 1/E 1 88401 10 | | | | 20000000 |
| 5,39 | Paid up equity share capital (Face value of ₹10/- each) Other Equity | 2,959.78 | 2,959.78 | 2,959.78 | 2,959.78 |
| de la | Outer Equity | | | | 98,393.58 |
| | Earnings per share (of ₹10 each) | | | | |
| | (a) Basic | 16.56 | . 2.62 | 9.85 | 34.59 |
| | (b) Diluted | 16.56 | 2.62 | 9.85 | 34.59 |
| | | | m. v. m | 2.00 | 21,27 |



CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033; Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

Notes:

- 1 The above Unaudited Consolidated Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on August 09, 2024. The Statutory Auditors have carried out a limited review of financial results. The Limited Review Report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com.
- 2 The Board of Directors have declared an interim dividend of ₹ 2/- per equity share at its meeting held on August 09, 2024.
- 3 The above Consolidated Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
- 4 The Group is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical & Formulation.
- 5 The Company's wholly owned subsidiary IIL Biologicals Limited has successfully completed the rights issue of Equity Shares of INR 200.00 Lakhs on June 28, 2024.
- 6 The figures of the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year-to-date figures for nine months ended December 31, 2023, respectively.

For and on behalf of the Board

Rajesh Kumar Aggarwal Managing Director DIN: 00576872

Place: Delhi Date: 09/08/2024

S S KOTHARI MEHTA & Co. LLP

DEVESH PAREKH & CO.

Chartered Accountants Plot No. 68, Okhla Industrial Area, Phase-III New Delhi - 110020

Chartered Accountants 675, Aggarwal Cyber Plaza-2, Netaji Subhash Place, Pitampura, Delhi-110034

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Insecticides (India) Limited
Delhi

Review Report on the Unaudited Consolidated Financial Results

- We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Insecticides
 (India) Limited ("the Parent or the Company"), its subsidiaries and its jointly controlled entity for the quarter
 ended June 30, 2024 ("the Statement"), attached herewith, being submitted by the Parent pursuant to the
 requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,
 as amended.
- 2. This statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting" ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entities:

Parent

Insecticides (India) Limited

Subsidiary
IIL Biologicals Limited
IIL Overseas DMCC (Dubai)

Jointly Controlled Entity
OAT & IIL India Laboratories Private Limited





S S KOTHARI MEHTA & Co. LLP

Chartered Accountants Plot No. 68, Okhla Industrial Area, Phase-III New Delhi -110020

DEVESH PAREKH & CO.

Chartered Accountants 675, Aggarwal Cyber Plaza-2, Netaji Subhash Place, Pitampura, Delhi-110034

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the other matters referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Other Matters:

a) The accompanying unaudited consolidated financial results include the unaudited financial result of one subsidiary, which reflect total revenue of Rs. 59.65 Lacs, total net profit/ (loss) after tax of Rs. (15.82) Lacs and total comprehensive income/(loss) of Rs. (15.82) Lacs for the quarter ended June 30, 2024, which have been reviewed by one of the joint auditors, individually.

The reports on the unaudited financial results of above entity have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph 3 above.

Our conclusion on the statement is not modified in respect of the above matters.

b) The Statement also includes the financial results of a foreign subsidiary which have not been reviewed by their auditors, whose financial results reflect total revenue of Rs. Nil, total net loss after tax of Rs. (1.31) lacs and total comprehensive loss of Rs. (1.31) lacs for the quarter ended June 30, 2024, as considered in the unaudited consolidated financial results. The unaudited consolidated financial results also include the company's share of net profit of Rs. 17.83 lacs and total comprehensive income of Rs. 14.61 lacs for the quarter ended June 30, 2024, as considered in the unaudited consolidated financial results.

These unaudited financial results have not been reviewed by their auditors and have been approved and furnished to us by the management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of said subsidiary and jointly controlled entity, is based solely on such unaudited financial results. According to the information and explanations given to us by the Management, these financial results are not material to the group.

Our conclusion on the statement is not modified in respect of the above matters.

For S S Kothari Mehta & Co. LLP

Chartered Accountants

FRN: 000756N/ N500441

Vijay Kumar

Partner

Membership number: 092671

UDIN: 24092671BKFBQQ8406

Place: Delhi

Date: 9th August, 2024

For Devesh Parekh & Co.

Chartered Accountants

FRN: 013338N

Devesh Parekh

Partner

Membership number: 092160

UDIN: 240921 GOBKDGAC

Place: Delhi

Date: 9th August, 2024





Annexure II

Regd. & Corporate Office: 401-402, Lusa Tower

Details of appointment as required under Regulation 30 read with Para A (7) of Part A of Schedule III to the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023

| S. No. | Particulars | Description |
|--------|--|--|
| 1. | Name | Mr. Dushyant Sood, Chief Marketing Officer (CMO) |
| 2. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Appointment |
| 3. | Date of appointment/eessation (as applicable) & Term of appointment | August 09, 2024 |
| 4. | Brief profile (in case of appointment); | Mr. Dushyant Sood brings with him over 3 decades of rich experience and a proven track record of success in Sales & Marketing functions in the agrochemical & seed industry His key strengths are Product Renewal Strategies, Portfolio Management, Product Monetization, Generating Revenue & Profitability, Business Re-Modelling, Profit & Loss Management, Strategic Branding Initiative. His previous associations include PI Industries, E.I. Du Pont, Searle along with PHI Seeds. He was instrumental in the creation of strong brands like Kloben, Almix, Coragen, Ferterra, Galileo Sensa, Awkira, Osheen, Keefun, Brofreya |
| 5. | Disclosure of relationships between directors (in case of appointment of a director). | Not Applicable. |





Regd. & Corporate Office: 401-402, Lusa Tower

Details of appointment as required under Regulation 30 read with Para A of Part A of Schedule III to the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023

| S. No. | Particulars | Description |
|-----------|--|---|
| 1. | The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year; | The company has not commenced its business activities since incorporation. |
| 2. | Date on which the agreement for sale has been entered into; | No binding agreement has been entered into. The Board of Directors of the Company has agreed to the proposal for closure of operation of IIL Overseas DMCC, UAE at its meeting held on August 09, 2024, subject to the completion of all other regulatory requirements. |
| 3. | The expected date of completion of sale/disposal; | The date of closure is expected on or before September 30, 2024 |
| 4. | Consideration received from such sale/disposal; | Not Applicable |
| 5. | Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof; | Not Applicable |
| 6. | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"; | Not Applicable |
| 7. | Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with | Not Applicable |

ISO 9001, 14001 & OHSAS 18001

URS UNAS SO 9001

SO 9001

CERTIFIED COMPANY



Regd. & Corporate Office: 401-402, Lusa Tower Azadpur Commercial Complex, Delhi-110 033 Telefax: +91 1127679700-05 (6 Lines)

| | regulation 37A of LODR Regulations. | |
|----|--|----------------|
| 8. | Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale. | Not Applicable |